PTE - PTE STOCK NEWS

PolarityTE (Nasdaq: PTE) announced that an accredited investor will exercise warrants for 10,688,043 shares at $0.624, generating gross proceeds of $7,671,343, excluding fees. The investor will also receive an additional warrant for 8,016,033 shares at $1.20, with a purchase price of $1,002,004. The proceeds will be used for working capital and corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.

PolarityTE, Inc. (Nasdaq: PTE) has completed the target enrollment of 100 subjects for its randomized controlled trial assessing SkinTE® combined with standard care versus standard care alone for diabetic foot ulcers (DFUs). The primary endpoint focuses on the closure rates of index ulcers at 12 weeks. Topline results are expected to be announced during the Symposium on Advanced Wound Care (SAWC) in May 2021. CEO David Seaburg emphasized the milestone's significance, while CSO Nik Sopko praised the team's efforts during the pandemic.

PolarityTE, Inc. (Nasdaq: PTE) has closed a registered direct offering, selling 6,670,000 shares of common stock and 2,420,910 pre-funded warrants. The offering price for shares was $1.100 each, with immediate exercisable warrants priced at $1.20. Proceeds will be used for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. This transaction follows a shelf registration with the SEC. No offers or sales occurred in jurisdictions where prohibited.

PolarityTE, Inc. (Nasdaq: PTE) has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase of 9,090,910 shares of its common stock and accompanying warrants. The offering is priced at $1.10 per share, expected to yield approximately $10 million in gross proceeds for working capital and general corporate purposes. The registered direct offering is set to close on or about January 14, 2021, subject to standard conditions. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.

PolarityTE, Inc. (Nasdaq: PTE) has formed a strategic review committee aimed at enhancing shareholder value. The committee will evaluate operational strategies and practices to advance the regulatory process for SkinTE, along with potential future financings to support the company's objectives. Chairman Peter Cohen emphasized the commitment to maximizing shareholder value, believing the pursuit of a BLA for SkinTE could significantly benefit both patients and investors.

PolarityTE (Nasdaq: PTE) announced its participation in the H.C. Wainwright Virtual Bioconnect Conference on January 11, 2021. The presentation will be available via webcast starting at 6:00 a.m. Eastern Time. Interested individuals can access the webcast on the company's website or directly through the provided link. PolarityTE specializes in regenerative tissue products and biomaterials, focusing on patient-based manufacturing, which uses the patient's own tissue to promote effective healing and regeneration.

PolarityTE, Inc. (Nasdaq: PTE) has entered a securities purchase agreement with a healthcare-dedicated institutional investor to sell 10,688,043 shares of common stock and accompanying warrants at a purchase price of $0.7485. This registered direct offering is expected to yield approximately $8.0 million in gross proceeds, which will be used for working capital and general corporate purposes. Closing is anticipated around December 24, 2020. H.C. Wainwright & Co. acts as the exclusive placement agent. The securities are offered under an effective registration statement with the SEC.

PolarityTE, Inc. (Nasdaq: PTE) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application No. 14/954,335, marking the company’s first patent allowance in the U.S. The approved application pertains to its minimally polarized functional unit (MPFU) technology for regenerating skin tissue. This approval adds to the company's growing international patent portfolio, which now includes patents granted in countries like Japan, Canada, and the UK. CEO David Seaburg highlights this milestone as essential for protecting PolarityTE's regenerative medicine assets.

PolarityTE, Inc. (Nasdaq: PTE) announced total revenues of $3.34 million for Q3 2020, up from $1.40 million in Q3 2019. SkinTE sales reached $1.16 million, compared to $0.84 million the previous year, while contract service revenues were $2.18 million, including $1.75 million from COVID-19 testing. The net loss improved to $7.08 million from $22.98 million year-over-year. As of September 30, 2020, cash and equivalents stood at $23.19 million, down from $29.24 million at the end of 2019. Significant reductions in G&A and sales/marketing expenses contributed to lower losses.